

<b>NRC FORM 313M</b> (9-81) 10 CFR 35	<b>U.S. NUCLEAR REGULATORY COMMISSION</b> <b>APPLICATION FOR MATERIALS LICENSE – MEDICAL</b>	Approved by OMB 3150-0041 Expires 9-30-83
---	---	---

**INSTRUCTIONS** – Complete Items 1 through 26 if this is an initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to: Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee is subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.

<b>1.a. NAME AND MAILING ADDRESS OF APPLICANT</b> (institution, firm, clinic, physician, etc.) INCLUDE ZIP CODE  St. Joseph's Hospital Medical Center 2200 East Washington Street Bloomington, Illinois 61701  TELEPHONE NO.: AREA CODE (309) <u>662</u> <u>3311</u>	<b>1.b. STREET ADDRESS(ES) AT WHICH RADIOACTIVE MATERIAL WILL BE USED</b> (If different from 1.a.) INCLUDE ZIP CODE  Same.
<b>2. PERSON TO CONTACT REGARDING THIS APPLICATION</b> Sam Pontillo, Consultant Nuclear Medicine Associates TELEPHONE NO.: AREA CODE (216) <u>641</u> <u>5799</u>	<b>3. THIS IS AN APPLICATION FOR:</b> (Check appropriate item) a. <input type="checkbox"/> NEW LICENSE b. <input checked="" type="checkbox"/> AMENDMENT TO LICENSE NO. <u>12-00663-03</u> c. <input type="checkbox"/> RENEWAL OF LICENSE NO. _____
<b>4. INDIVIDUAL USERS</b> (Name individuals who will use or directly supervise use of radioactive material. Complete Supplements A and B for each individual.)  Refer to Item #8	<b>5. RADIATION SAFETY OFFICER (RSO)</b> (Name of person designated as radiation safety officer. If other than individual user, complete resume of training and experience as in Supplement A.)  Raymond Yin, M.D. with consultation from Nuclear Medicine Associates, Cleveland, Ohio 44125

**6.a. RADIOACTIVE MATERIAL FOR MEDICAL USE**

RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)	ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)
10 CFR 31.11 FOR IN VITRO STUDIES			IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM		
10 CFR 35.100, SCHEDULE A, GROUP I		AS NEEDED	PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES		
10 CFR 35.100, SCHEDULE A, GROUP II		AS NEEDED	PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP III			GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP IV		AS NEEDED	IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA		
10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED	XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
10 CFR 35.100, SCHEDULE A, GROUP VI					

**6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a.** (Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35, and NEED NOT BE LISTED.)

ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE
The purpose of this amendment is to update the authorized user list. Please refer to Item #8.  <div style="display: flex; justify-content: space-between;"> <span> <b>B506106793 B50524</b>  <b>REG3 LIC30</b>  <b>12-00663-03</b> </span> <span> <b>PDR</b> </span> </div>			<div style="border: 1px solid black; padding: 10px; margin: 0 auto; width: 80%;"> <b>RECEIVED</b>   <b>MAY 06 1985</b>   <b>REGION III</b> </div>

# INFORMATION REQUIRED FOR ITEMS 7 THROUGH 23

For Items 7 through 23, check the appropriate box(es) and submit a detailed description of all the requested information. Begin each item on a separate sheet. Identify the item number and the date of the application in the lower right corner of each page. If you indicate that an appendix to the medical licensing guide will be followed, do not submit the pages, but specify the revision number and date of the referenced guide: Regulatory Guide 10.8, Rev. \_\_\_\_\_ Date: \_\_\_\_\_

7. MEDICAL ISOTOPES COMMITTEE		15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL (Check One)	
<input type="checkbox"/>	Names and Specialties Attached; and	<input type="checkbox"/>	Appendix G Rules Followed; or
<input type="checkbox"/>	Duties as in Appendix B; or _____ (Check One)	<input type="checkbox"/>	Equivalent Rules Attached
<input type="checkbox"/>	Equivalent Duties Attached	16. EMERGENCY PROCEDURES (Check One)	
8. TRAINING AND EXPERIENCE		<input type="checkbox"/>	Appendix H Procedures Followed; or
<input type="checkbox"/>	Supplements A & B Attached for Each Individual User; and	<input type="checkbox"/>	Equivalent Procedures Attached
<input type="checkbox"/>	Supplement A Attached for RSO.	17. AREA SURVEY PROCEDURES (Check One)	
9. INSTRUMENTATION (Check One)		<input type="checkbox"/>	Appendix I Procedures Followed; or
<input type="checkbox"/>	Appendix C Form Attached; or	<input type="checkbox"/>	Equivalent Procedures Attached
<input type="checkbox"/>	List by Name and Model Number	18. WASTE DISPOSAL (Check One)	
10. CALIBRATION OF INSTRUMENTS		<input type="checkbox"/>	Appendix J Form Attached; or
<input type="checkbox"/>	Appendix D Procedures Followed for Survey Instruments; or _____ (Check One)	<input type="checkbox"/>	Equivalent Information Attached
<input type="checkbox"/>	Equivalent Procedures Attached; and	19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS (Check One)	
<input type="checkbox"/>	Appendix D Procedures Followed for Dose Calibrator; or _____ (Check One)	<input type="checkbox"/>	Appendix K Procedures Followed; or
<input type="checkbox"/>	Equivalent Procedures Attached	<input type="checkbox"/>	Equivalent Procedures Attached
11. FACILITIES AND EQUIPMENT		20. THERAPEUTIC USE OF SEALED SOURCES	
<input type="checkbox"/>	Description and Diagram Attached	<input type="checkbox"/>	Detailed Information Attached; and
12. PERSONNEL TRAINING PROGRAM		<input type="checkbox"/>	Appendix L Procedures Followed; or _____ (Check One)
<input type="checkbox"/>	Description of Training Attached	<input type="checkbox"/>	Equivalent Procedures Attached
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL		21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon - 133)	
<input type="checkbox"/>	Detailed Information Attached	<input type="checkbox"/>	Detailed Information Attached
14. PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS (Check One)		22. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS	
<input type="checkbox"/>	Appendix F Procedures Followed; or	<input type="checkbox"/>	Detailed Information Attached
<input type="checkbox"/>	Equivalent Procedures Attached	23. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.b	
<input type="checkbox"/>		<input type="checkbox"/>	Detailed Information Attached

## 24. PERSONNEL MONITORING DEVICES

	TYPE <small>(Check appropriate box)</small>	FILM	TLD	OTHER (Specify)	SUPPLIER	EXCHANGE FREQUENCY
a. WHOLE BODY	<input checked="" type="checkbox"/>	FILM			No Change	
	<input type="checkbox"/>	TLD				
	<input type="checkbox"/>	OTHER (Specify)				
b. FINGER	<input type="checkbox"/>	FILM			No Change	
	<input checked="" type="checkbox"/>	TLD				
	<input type="checkbox"/>	OTHER (Specify)				
c. WRIST	<input type="checkbox"/>	FILM				
	<input type="checkbox"/>	TLD				
	<input type="checkbox"/>	OTHER (Specify)				

d. OTHER (Specify)

## 25. FOR PRIVATE PRACTICE APPLICANTS ONLY

a. HOSPITAL AGREEING TO ACCEPT PATIENTS CONTAINING RADIOACTIVE MATERIAL

NAME OF HOSPITAL

MAILING ADDRESS

CITY

STATE

ZIP CODE

b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.

c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.

## 26. CERTIFICATE

(This item must be completed by applicant)

The applicant and any official executing this certificate on behalf of the applicant named in Item 1a certify that this application is prepared in conformity with Title 10, Code of Federal Regulations, Parts 30 and 35, and that all information contained herein, including any supplements attached hereto, is true and correct to the best of our knowledge and belief.

a. LICENSE FEE REQUIRED  
(See Section 170.31, 10 CFR 170)

(1) LICENSE FEE CATEGORY:

7C

(2) LICENSE FEE ENCLOSED: \$

120.00

b. APPLICANT OR CERTIFYING OFFICIAL (Signature)

X

(1) NAME (Type of Print)

X

Kenneth J. Natzke

(2) TITLE

X

Administrator

c. DATE

X

April 30, 1985

## PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on NRC Form 313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

1. **AUTHORITY** Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
2. **PRINCIPAL PURPOSE(S)** The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.
3. **ROUTINE USES** The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.
4. **WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION** Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.
5. **SYSTEM MANAGER(S) AND ADDRESS** Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

**NAME OF AUTHORIZED USER**

**AUTHORIZATION**

Please amend to add:

Charles W. Keiser, M.D.

Groups I, II, III  
I-131 for hyperthyroidism

For training and experience please refer to Amendment #43, NRC  
license #12-01167-02 for St. Francis Medical Center, Peoria, Illinois.  
See attached.

Please amend to add:

Revathi Swaminathan, M.D.

I-125 Seeds

For training and experience please refer to NRC license #12-03567-02  
for Methodist Medical Center, Peoria, Illinois. See attached.

Item #8  
1 of 1 page  
Prepared: 4/15/85  
Lic. # 12-00663-03



MATERIALS LICENSE  
SUPPLEMENTARY SHEET

12-01167-02

Docket or Reference number

030-01394

Amendment No. 43

Charles W. Keiser, M.D.

Groups I, II and III

Xenon-133

Iodine-131 for treatment of  
hyperthyroidism

In vitro studies

Irving J. Weigenberg, M.D.

Iodine-125 seeds

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated October 6, 1983, August 16, 1983 (except Item No. 15), April 13, 1984, July 24, 1984 and November 13, 1984; ALARA Program dated August 16, 1983; and letters dated May 22, 1984 and September 6, 1984. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

~~203200275~~ 19

For the U.S. Nuclear Regulatory Commission

DEC 20 1984

e \_\_\_\_\_

By

*Patricia Vickerton*  
Materials Licensing Section, Region III

CONTROL NO. 78877

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

12-03567-02

Docket or Reference number

030-01450

Amendment No. 45

Methodist Medical Center  
221 Northeast Glen Oak Avenue  
Peoria, IL 61636

In accordance with application dated February 13, 1985, License Number 12-03567-02 is amended as follows:

Conditions 12. and 22. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Robert S. Malcolm, M.D.

Groups I through VI  
Xenon-133

Craig A. Fenton, M.D.

Groups I through V  
Xenon-133

Irving J. Weigenberg, M.D.

Groups IV, V and VI

Eric Frow

In vitro studies

Revathi Swaminathan, M.D.

Group VI

John J. Taraska, M.D.

Group I  
In vitro studies

22. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated February 25, 1983 and February 13, 1985; letters dated May 13, 1982, November 8, 1982, February 23, 1983; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

~~8504/00640~~ LP

For the U.S. Nuclear Regulatory Commission

Date MAR 27 1985

By

William J. Chilton  
Materials Licensing Section, Region III

CONTROL NO. 78877